FINWIRES · TerminalLIVE
FINWIRES

Regenxbio Seen on Track for Duchenne Approval as Data Strengthens, RBC Says

By

Regenxbio's (RGNX) Duchenne muscular dystrophy gene therapy appears approvable, with efficacy comparable to Sarepta Therapeutics (SRPT) and a more favorable safety profile, as the company moves toward submitting its rolling biologics license application, RBC Capital Markets said Thursday in a report.

Regenxbio is on track to file the first module of the BLA this quarter and expects to complete the submission in Q1 2027, RBC said. By that time, the company anticipates having functional data from roughly half of the 30 patients in its fully enrolled pivotal trial, the report said.

RBC said the confirmatory study is also fully enrolled and designed to compare two-year functional outcomes against established benchmarks for disease progression, while a larger placebo-controlled trial recommended by European regulators is planned for 2027 to support global filings.

RBC reiterated its outperform rating on Regenxbio stock and $19 price target.

Price: $10.47, Change: $-0.81, Percent Change: -7.18%

Related Articles

Wire

Century Aluminum Q2 Adjusted Earnings, Revenue Rise

Century Aluminum (CENX) reported Q2 adjusted earnings late Thursday of $2.46 per diluted share, up from $0.30 a year earlier.Three analysts polled by FactSet expected $2.33.Revenue for the three months ended June 30 rose to $752.1 million from $628.1 million a year earlier.Four analysts surveyed by FactSet expected $817.2 million.The company's shares rose 1.6% in after-hours trading.

$CENX
Wire

JFrog Q2 Non-GAAP Earnings, Revenue Rise; Shares Gain After Hours

JFrog (FROG) reported Q2 non-GAAP earnings late Thursday of $0.27 per diluted share, up from $0.18 a year earlier.Analysts polled by FactSet expected $0.24.Revenue in the three months ended June 30 rose to $163.8 million from $127.2 million a year earlier.Analysts projected $155.6 million.The company expects Q3 non-GAAP EPS of $0.22 to $0.24 on revenue of $164 million to $166 million. Analysts project EPS of $0.22 on revenue of $159 million.JFrog boosted full-year guidance to non-GAAP EPS of $0.96 to $1.00 on revenue of $648 million to $652 million. The prior forecast was EPS of $0.93 to $0.97 on revenue of $628 million to $632 million.Analysts expect EPS of $0.95 on revenue of $632.9 million.JFrog shares jumped 13% in after-hours trading.

$FROG
Wire

Reinsurance Group of America Q2 Adjusted Earnings, Revenue Rise

Reinsurance Group of America (RGA) reported Q2 adjusted earnings late Thursday of $8.89 per diluted share, up from $4.72 a year earlier.Analysts polled by FactSet expected $6.50.Revenue in the three months ended June 30 rose to $6.64 billion from $5.6 billion a year earlier.Analysts projected $6.67 billion.The company's shares rose 1.6% in after-hours trading.

$RGA